108 related articles for article (PubMed ID: 31549889)
1. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R; Gibiansky L; Lu T; Li X; Lu D; Li C; Girish S; Wang J; Boyer M; Shankar N; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Leuk Lymphoma; 2020 Jan; 61(1):56-65. PubMed ID: 31549889
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
3. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
[TBL] [Abstract][Full Text] [Related]
4. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Okubo S; Ogawa N; Sakai M; Nishimura Y; Chyla B; Sun Y; Maruyama D
Int J Hematol; 2023 Oct; 118(4):526-528. PubMed ID: 37581752
[No Abstract] [Full Text] [Related]
7. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract][Full Text] [Related]
8. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Lew TE; Bennett R; Lin VS; Whitechurch A; Handunnetti SM; Marlton P; Shen Y; Mulligan SP; Casan J; Blombery P; Tam CS; Roberts AW; Seymour JF; Thompson PA; Anderson MA
Blood Adv; 2024 Mar; 8(6):1439-1443. PubMed ID: 38231032
[No Abstract] [Full Text] [Related]
10. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
AlZahrani A; Alsuhebany N; Tailor IK; Alrajhi AM
Hematology; 2024 Dec; 29(1):2296809. PubMed ID: 38149670
[TBL] [Abstract][Full Text] [Related]
11. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F; Innocenti I; Reda G; Visentin A; Vitale C; Piciocchi A; Fresa A; Leone MMA; Farina L; Quaresmini G; Baratè C; Giordano A; Ferrari A; Angeletti I; De Paolis MR; Malerba L; Chiurazzi F; Loseto G; Catania G; Sportoletti P; Scortechini I; Moia R; Gentile M; Rigolin GM; Mattiello V; Gattei V; Coscia M; Trentin L; Foà R; Cuneo A; Laurenti L
Hematol Oncol; 2023 Dec; 41(5):877-883. PubMed ID: 37392141
[TBL] [Abstract][Full Text] [Related]
12. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M; Thus YJ; Robrecht S; Mellink CHM; van der Kevie-Kersemaekers AM; Dubois J; von Tresckow J; Patz M; Gregor M; Thornton P; Staber PB; Tadmor T; Levin MD; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Janssens A; Christiansen I; Nösslinger T; Baumann M; Hebart H; Gaska T; Regelink JC; Dompeling EC; Lindström V; Juliusson G; Widmer A; Goede J; Goldschmidt N; Simon F; De Silva N; Fink AM; Fischer K; Wendtner CM; Ritgen M; Brüggemann M; Tausch E; Spaargaren M; Eldering E; Stilgenbauer S; Niemann CU; Hallek M; Eichhorst B; Kreuzer KA; Kater AP
Blood; 2023 Aug; 142(5):446-459. PubMed ID: 37172204
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia.
Yang L; Banerji V
Lancet Oncol; 2024 Apr; 25(4):413-414. PubMed ID: 38547887
[No Abstract] [Full Text] [Related]
14. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Rogers KA
Lancet Oncol; 2024 Jun; 25(6):685-687. PubMed ID: 38821078
[No Abstract] [Full Text] [Related]
15. Upfront therapy: the case for continuous treatment.
Tam CS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):55-58. PubMed ID: 34889433
[TBL] [Abstract][Full Text] [Related]
16. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Huntington SF; Manzoor BS; Puckett JT; Kamal-Bahl S; Alhasani H; Ravelo A; Jawaid D; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2316-2323. PubMed ID: 37732602
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Autore F; Visentin A; Deodato M; Vitale C; Galli E; Fresa A; Fazzi R; Sanna A; Olivieri J; Scortechini I; Del Principe MI; Sportoletti P; Schiattone L; Maschio N; Facchinelli D; Marchesi F; Coscia M; Tedeschi A; Trentin L; Innocenti I; Candoni A; Busca A; Pagano L; Laurenti L
Am J Hematol; 2024 May; 99(5):982-984. PubMed ID: 38343033
[No Abstract] [Full Text] [Related]
18. Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929430
[No Abstract] [Full Text] [Related]
19. Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial.
Roeker LE; Woyach JA; Cheah CYY; Coombs CC; Shah NN; Wierda WG; Patel MR; Lamanna N; Tsai DE; Nair BC; Wang C; Zhao X; Liu D; Radtke D; Chapman S; Marella N; McNeely SC; Brown JR
Blood; 2024 Jun; ():. PubMed ID: 38861666
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Schieber M; Ma S
Blood Lymphat Cancer; 2019; 9():9-17. PubMed ID: 32009829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
